← Back to Search

Blood Flow Imaging for Glaucoma

N/A
Recruiting
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will investigate if blood flow imaging can help diagnose glaucoma. Participants will have tests to measure blood pressure, heart rate, etc & be imaged using XyCAM RI & other tools.

Who is the study for?
This trial is for adults with binocular vision who can consent, are healthy or need glaucoma assessment, or have moderate to severe glaucoma in one eye. It's not for those with significant eye issues like cataracts, past surgeries (except some), other diseases besides glaucoma, narrow angles, bad reactions to certain drugs, high refractive error (>15 diopters), or women who are pregnant/nursing.
What is being tested?
The study tests the XyCAM RI and FC devices' ability to use blood flow imaging for managing glaucoma. Participants will undergo various imaging procedures including fundus photography and ocular blood flow monitoring while breathing pure oxygen through a mask.
What are the potential side effects?
Potential side effects may include discomfort from bright lights during imaging, temporary blurred vision due to pupil dilation with tropicamide, and possible dizziness or lightheadedness when inhaling pure oxygen.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood flow velocity measure

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Pre-perimetric GlaucomaExperimental Treatment1 Intervention
All participants with pre-perimetric glaucoma will be first be imaged pre-intervention.
Group II: GlaucomaExperimental Treatment1 Intervention
All participants with glaucoma will be first be imaged pre-intervention.
Group III: ControlExperimental Treatment1 Intervention
All control participants will be first be imaged pre-intervention.

Find a Location

Who is running the clinical trial?

National Eye Institute (NEI)NIH
558 Previous Clinical Trials
1,408,321 Total Patients Enrolled
42 Trials studying Glaucoma
16,964 Patients Enrolled for Glaucoma
University of Maryland, BaltimoreLead Sponsor
716 Previous Clinical Trials
380,964 Total Patients Enrolled
2 Trials studying Glaucoma
100 Patients Enrolled for Glaucoma
Vasoptic Medical, IncUNKNOWN
Grace Forbes, MSStudy DirectorUniversity of Maryland, Baltimore

Media Library

Pre-perimetric Glaucoma Clinical Trial Eligibility Overview. Trial Name: NCT05726058 — N/A
Glaucoma Research Study Groups: Pre-perimetric Glaucoma, Glaucoma, Control
Glaucoma Clinical Trial 2023: Pre-perimetric Glaucoma Highlights & Side Effects. Trial Name: NCT05726058 — N/A
Pre-perimetric Glaucoma 2023 Treatment Timeline for Medical Study. Trial Name: NCT05726058 — N/A
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top